Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 533-547

  Sfoungaristos, Stavros ^a   Giannitsas, Konstantinos ^a   Perimenis, Petros ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bevacizumab; Chemotherapy; Cytokines; Growth factors; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitors; Vaccine

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; DENDRITIC CELL VACCINE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GEFITINIB; GEMCITABINE; IMATINIB; INTERFERON; INTERLEUKIN 2; IXABEPILONE; LAPATINIB; PACLITAXEL; PANITUMUMAB; PEPTIDE VACCINE; PTK 7871IZK; RENIALE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VITESPEN;

ABDOMINAL PAIN; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLOOD TOXICITY; CANCER IMMUNIZATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SURVIVAL; TREATMENT OUTCOME;

EID: 79951594871     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.524928     Document Type: Review

References (116)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
2. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27(2):177-86 (Pubitemid 30205372)
3. Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. Semin Urol Oncol 2001;19(2):88-97 (Pubitemid 32416471)
4. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3):1071-6 (Pubitemid 38327529)
5. Warren M, Venner PM, North S, et al. A pulation-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2009;3(4):281-9
6. Thyavihally YB, Mahantshetty U, Chamarajanagar RS, et al. Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 2005;3:48
7. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-5 (Pubitemid 29246458)
8. Yu F, White SB, Zhao Q, Lee FS. Dynamic, site-pecific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res 2001;61(10):4136-42 (Pubitemid 32720982)
9. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
10. Hara S, Oya M, Mizuno R. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005;16:928-33 (Pubitemid 40903919)
11. Shin Lee J, Seok Kim H, Bok Kim Y, et al. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 2003;84:166-72
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(2):2271-81 (Pubitemid 46849157)
13. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34 (Pubitemid 46089673)
14. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11 (Pubitemid 350296300)
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Eng J Med 2007;356(2):115-24 (Pubitemid 46089672)
16. Kay A, Motzer RJ, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO Genitourinary Cancers Symposium (Abstract No 278); 26 - 29 February 2009 Orlando, Florida
17. Patard JJ, Pouessel D, Bensalah K, et al. Targeted therapy in renal cell carcinoma. World J Urol 2008;26(2):135-40
18. Ikemoto S, Sugimura K, Yoshida N, et al. Comparative antitumor activity of 5-fluorouracil and 5¢-deoxy-5- fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines. Urol Int 2004;73(4):348-53 (Pubitemid 39664309)
19. Van Veldhuizen PJ, Hussey M, Lara PN Jr, et al. A Phase II Study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009. [Epub ahead of print]
20. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study. Lancet Oncol 2010;11(4):350-7
21. Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008;180(3):867-72
22. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004;91(10):1763-8 (Pubitemid 39664962)
23. Segota E, Mekhail T, Olencki T, et al. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol 2007;25(1):46-52 (Pubitemid 46027613)
24. Marur S, Eliason J, Heilbrun LK, et al. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. Urology 2008;72(4):898-902
25. Bylow KA, Atkins MB, Posadas EM, et al. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):39-42
26. Posadas EM, Undevia S, Manchen E, et al. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther 2007;6(4):490-3 (Pubitemid 47328321)
27. Huang H, Menefee M, Edgerly M, et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010;16(5):1634-41
28. Amato RJ, Jac J, Hernandez-McClain J. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 2008;6(2):73-8
29. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133-41 (Pubitemid 41702632)
30. Negrier S, Perol D, Ravaud A, et al. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res 2008;14(18):5907-12
31. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11(10):3714-21 (Pubitemid 40685588)
32. Negrier S, Perol D, Ravaud C, et al. Medroxyprogesterone, interferon alfa-2a, interleukin-2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. Cancer 2007;110(11):2468-77 (Pubitemid 350174932)
33. Akaza H, Kawai K, Tsukamoto T, et al. Successful outcomes using combination therapy of interleukin-2 and interferon-(alpha) for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol 2010. [Epub ahead of print]
34. Gore ME, Griffin CL, Hancock B, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010;375(9715):641-8
35. Garcia JA, Rini BI, Mekhail T, et al. A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). J Clin Onc 2007;25:abstract 5103
36. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32(2):181-5
37. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425
38. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594-9 (Pubitemid 38264176)
39. Fishman M, Hunter TB, Soliman H, et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 2008;31(1):72-80 (Pubitemid 351619406)
40. Pizza G, De Vinci C, Lo Conte G, et al. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol 2004;50(6):175-83 (Pubitemid 40220741)
41. Fishman M, Hunter TB, Soliman H, et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 2008;31(1):72-80 (Pubitemid 351619406)
42. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10(14):4699-708 (Pubitemid 38955520)
43. Barbuto JA, Ensina LF, Neves AR, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004;53(12):1111-18 (Pubitemid 39506400)
44. Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/ autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007;30(7):749-61 (Pubitemid 47480758)
45. Wei YC, Sticca RP, Li J, et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol Rep 2007;18(3):665-71
46. Kim JH, Lee Y, Bae YS, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125(3):257-67 (Pubitemid 350116707)
47. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145- 54
48. Peccatori J, Barkholt L, Demirer T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005;104(10):2099-103 (Pubitemid 41579955)
49. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004;103(2):435-41 (Pubitemid 38140070)
50. Rini BI, Halabi S, Barrier R, et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant 2006;12(7):778-85 (Pubitemid 43899414)
51. Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 2006;16(5):337-41 (Pubitemid 44231708)
52. Larkin JM, Eisen T. Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag 2006;2(1):87-98 (Pubitemid 43950068)
53. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
54. Negrier S, Jager E, Porta C, et al. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol 2009. [Epub ahead of print]
55. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25(22):3288-95 (Pubitemid 47325614)
56. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25(22):3296-301 (Pubitemid 47325615)
57. Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010;116(1):57-65
58. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(8):1280-9
59. Di Lorenzo G, Carteni G, Autorino R. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27(27):4469-74
60. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008:26;abstract 5123
61. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179(1):81-6 (Pubitemid 350216728)
62. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127-31
63. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36 (Pubitemid 41094421)
64. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101(10):1717-23
65. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24 (Pubitemid 46630489)
66. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-7 (Pubitemid 47538608)
67. Thompson Coon JS, Liu Z, Hoyle M. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009;101(2):238-43
68. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182(1):29-34
69. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115(1):61-7
70. Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):28-33
71. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432-9
72. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):24-7
73. Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010;40(3):194-202
74. Yoo C, Kim JE, Lee JL, et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010. [Epub ahead of print]
75. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet 2007;8(11):975-84 (Pubitemid 47629888)
76. Trask PC, Bushmakin AG, Cappelleri JC, et al. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 2008;47(5):843-51 (Pubitemid 351882727)
77. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462-8
78. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8
79. Polite BN, Desai AA, Manchen B, et al. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer 2006;4(4):275-80 (Pubitemid 43779885)
80. Ryan CW, Vuky J, Chan JS, et al. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Invest New Drugs. 2009. [Epub ahead of print]
81. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol 2008;26:abstract 5047
82. De Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008;14(17):5548-54
83. Bhargava P, Esteves B, Nosov D A, et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 2009;27(Suppl):abstract 5032
84. Bhargava P, Esteves B, Al-Adhami M, et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2010;28(Suppl):abstract 4599
85. Bhargava P.Esteves B.Al-Adhami M.et al Effect of hypertension nephrectomy and prior treatment on the efficacy of tivozanib AV-951 in a phase II randomized discontinuation trial RDT in patients with renal cell carcinoma RCC. ASCO Genitourinary Cancers Symposium(Abstract No 342); 5 - 7 March 2010; Marriott, San Francisco
86. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69(20):8009-16
87. Eder JP, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 2007;25(Suppl):abstract 3526
88. Ross RW, Stein M, Sarantopoulos J, et al. A phase II study of the c- Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol 2007;25(Suppl):abstract 15601
89. Frampton JE, Keating GM. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma. BioDrugs 2008;22(2):113-20 (Pubitemid 351414752)
90. Escudier B, Bellmunt J, Negrier S. Phase III Trial of Bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010. [Epub ahead of print]
91. Rini BI, Halabi S, Rosenberg JE, et al. Phase III Trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010. [Epub ahead of print]
92. Hainsworth JD, Spigel DR, Burris HA, et al. Phase II Trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010. [Epub ahead of print]
93. Chung EK, Posadas EM, Kasza K, et al. A Phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2010. [Epub ahead of print]
94. Pastorelli D, Zustovich F, Faggioni G, et al. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma. Anticancer Drugs 2010;21(2):210-13
95. Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010;102(1):80-6
96. Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(25):4076-81
97. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90(5):985-90 (Pubitemid 38495816)
98. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006;175(1):57-62 (Pubitemid 41797084)
99. Siebels M, Rohrmann K, Oberneder R, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX ((R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2010. [Epub ahead of print]
100. Dutcher JP, De Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202-9
101. Hudes GR, Berkenblit A, Feingold J, et al. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009;36(Suppl 3):S26-36
102. Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 2010;102(10):1456-60
103. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
104. Ravaud A, Hawkins R, Gardner JP, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008;26(14):2285-91
105. Jermann M, Stahel RA, Salzberg M, et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 2006;57(4):533-9 (Pubitemid 43087597)
106. Amato RJ, Jac J, Hernandez-McClain J. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anticancer Drugs 2008;19(5):527-33 (Pubitemid 351556404)
107. Motzer RJ, Hudes GR, Ginsberg MS. Phase I/II Trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 2010. [Epub ahead of print]
108. Hainsworth JD, Sosman JA, Spigel DR. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23(31):7889-96 (Pubitemid 46657387)
109. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41 (Pubitemid 350035309)
110. Hainsworth JD, Spigel DR, Sosman JA, et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007;5(7):427-32 (Pubitemid 351219695)
111. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27(34):5788-93
112. Lin CC, Calvo E, Papadopoulos KP, et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009;63(6):1065-71
113. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22(15):3003-15 (Pubitemid 41103711)
114. Ljungberg B, Hanbury DC, Kuczyk MA, et al. European association of urology guideline froup for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 2007;51(6):1502-10
115. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25(29):4562-8 (Pubitemid 350035313)
116. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26(12):1987-92